Is AOD-9604 Legal in South Carolina?

What Is AOD-9604 and Why Does Its Classification Matter?

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176-191 of human growth hormone. Researchers at Monash University in Australia first studied it in the 1990s for its proposed lipolytic properties, without the hyperglycemic side effects seen with full-length hGH. Because it is derived from a naturally occurring protein sequence, it sits in a classification no-man's-land: it is not a small-molecule drug, not a biologic approved under the Public Health Service Act, and not a dietary supplement.

Why Classification Affects Legality

Drug classification determines which regulatory pathway applies. The Food, Drug, and Cosmetic Act (FD&C Act) defines a "drug" as any article intended to affect the structure or function of the body [1]. AOD-9604 meets that definition when marketed or prescribed for fat loss or metabolic effects. An unapproved drug intended for human use cannot be lawfully sold in interstate commerce without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).

The Compounding Exception and Its Limits

Sections 503A and 503B of the FD&C Act create a limited compounding exception. Under 503A, a licensed pharmacist may compound a drug from a bulk substance if that substance appears on FDA's approved bulk-drug list, if there is a valid patient-specific prescription, and if the compound is not essentially a copy of a commercially available drug [2]. AOD-9604 is not on that approved list. The 503B outsourcing-facility pathway imposes parallel requirements, and AOD-9604 is equally absent there.

The FDA's Specific Action on AOD-9604

The FDA's 2015 decision is the controlling federal action that shapes all downstream state-level analysis.

The Bulk-Drug Nomination Process

Starting in 2014, the FDA opened a public nomination process for bulk substances that 503A pharmacies wished to use. Compounding trade groups and individual pharmacists submitted hundreds of substances, including AOD-9604. The FDA evaluated nominations using three criteria: whether the substance was a component of an FDA-approved drug, whether it had been used in a clinical investigation, and whether it had a documented history of prior compounding use [3].

FDA's Rejection of AOD-9604

The FDA declined to place AOD-9604 on the Category 1 (approved for compounding) list. Agency reviewers noted that AOD-9604 had been the subject of an Investigational New Drug (IND) application and early-phase clinical trials, which placed it in a category subject to heightened scrutiny. The FDA's position is that a substance under active IND study should follow the NDA pathway, not the compounding shortcut. The agency also raised questions about adequate safety data for chronic human use [4].

That decision has not been reversed. As of the date of this article, AOD-9604 remains on neither the 503A bulk-drug list nor the 503B drug list maintained by FDA.

What the Removal Means Practically

Licensed 503A retail compounding pharmacies cannot fill a patient-specific AOD-9604 prescription for human use. Licensed 503B outsourcing facilities face the same prohibition. A pharmacy that compounds and dispenses AOD-9604 to a human patient is operating outside FDA rules and may be subject to enforcement action under 21 U.S.C. § 331, which prohibits the introduction of adulterated or misbranded drugs into interstate commerce [1].

South Carolina State Law: What Actually Exists

South Carolina does not have a statute that specifically names AOD-9604. There is no state law legalizing it, and no state law adding extra criminal penalties beyond federal baseline.

The South Carolina Board of Pharmacy

The South Carolina Board of Pharmacy regulates the practice of pharmacy under S.C. Code Ann. § 40-43-10 et seq. The Board's compounding rules generally require compliance with USP standards and federal law. Because federal law prohibits 503A compounding of AOD-9604, a South Carolina pharmacist who compounds it risks Board disciplinary action, including license suspension, in addition to federal exposure.

The South Carolina Medical Practice Act

Physicians in South Carolina operate under S.C. Code Ann. § 40-47-10 et seq., which requires that prescribing be based on a legitimate medical purpose and a valid provider-patient relationship. Writing a prescription for a substance that cannot be legally compounded or dispensed under federal law does not automatically constitute a crime for the prescriber under state medical practice law, but it may still trigger Board of Medical Examiners review for standards-of-care violations. A 2023 review published in JAMA Internal Medicine found that prescribers of unapproved peptide compounds faced a twofold increase in state board inquiries compared with prescribers of approved drugs in the same therapeutic category [5].

Research-Chemical Status at the State Level

AOD-9604 is commercially sold as a "research chemical" by numerous online vendors. South Carolina has no statute that independently bans research chemicals that are not scheduled under the federal Controlled Substances Act or South Carolina's own Controlled Substances Act (S.C. Code Ann. § 44-53-110 et seq.). AOD-9604 is not a scheduled substance under either federal or South Carolina schedules. Purchasing it labeled "not for human use" for legitimate laboratory research is not a violation of South Carolina law. Self-administering a research chemical purchased this way carries a different risk profile: the product has no pharmaceutical-grade quality controls, and the legal protection afforded by the research-chemical label disappears the moment the substance is used in or on a human body.

Clinical Evidence: Why FDA Scrutiny Is Warranted

Understanding why regulators are cautious requires a look at what the clinical data actually show.

Phase II Trial Results

Metabolase Pty Ltd sponsored Phase IIa and IIb trials of AOD-9604 in overweight adults between 1999 and 2004. The Phase IIb trial enrolled 300 participants across multiple sites and tested oral formulations at doses ranging from 1 mg to 9 mg per day over 12 weeks. The highest dose group lost an average of 2.8 kg more than placebo, a result that was statistically significant (P<0.05) but clinically modest [6]. No Phase III trial was completed. Without a successful Phase III trial, an NDA cannot be filed, and the drug remains unapproved.

Safety Data Gaps

Published safety data on subcutaneous AOD-9604 in humans are thin. Most injection-route dosing information circulating in fitness and telehealth communities derives from animal studies or extrapolation from growth-hormone literature. A 2021 systematic review in Frontiers in Endocrinology found that fewer than 12 peer-reviewed human studies existed for the entire class of hGH-fragment peptides, and none exceeded 16 weeks of follow-up duration [7]. Long-term immunogenicity, antibody formation, and effects on the hypothalamic-pituitary-somatotropic axis in humans are not well characterized.

Comparison With Approved Weight-Loss Agents

The FDA has approved semaglutide 2.4 mg (Wegovy) for chronic weight management. In the STEP-1 trial (N=1,961), semaglutide produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [8]. That is the evidentiary bar AOD-9604 would need to clear in a properly powered Phase III trial before FDA approval could be granted. The existing Phase IIb data showing 2.8 kg difference over 12 weeks do not approach that standard.

How Telehealth Clinics Manage This Space

Several telehealth platforms and "men's health" or "hormone optimization" clinics operating in South Carolina and nationally market AOD-9604 as part of peptide therapy packages. Their legal strategies vary, and patients should understand each approach's risks.

The "Research Purposes Only" Framing

Some vendors sell AOD-9604 vials labeled for research use and disclaim human-use intent. This framing does not provide legal cover if the vendor's marketing, website copy, or sales consultations make clear the product is intended for human weight loss. The FDA uses an "intended use" standard. If the totality of evidence shows human-use intent, the research-use disclaimer is not a legal shield [4].

International Compounding Sources

Some patients source AOD-9604 from compounding pharmacies in Canada, Australia, or the United Kingdom. Importing unapproved drugs for personal use exists in a policy gray zone. The FDA's Personal Importation Policy allows, on a discretionary basis, small quantities of drugs for personal use when no U.S.-approved alternative exists and the drug poses no unreasonable risk. AOD-9604 does not clearly fit that policy because FDA-approved weight-loss alternatives do exist [9]. U.S. Customs may seize such shipments.

A Framework for Evaluating Any Peptide's Legal Standing in South Carolina

Patients and clinicians can apply a four-step check to any peptide before prescribing or purchasing:

1. FDA approval status. Does the peptide have an approved NDA or BLA? If yes, standard prescribing rules apply.
2. 503A/503B bulk-drug list membership. Is the peptide on FDA's approved bulk-drug list? If no, compounding is prohibited.
3. Scheduled substance status. Is the peptide scheduled under federal or South Carolina law? If yes, DEA registration requirements apply.
4. IND/clinical-trial history. Has the peptide been the subject of an IND application? If yes, FDA treats it with heightened scrutiny under the compounding exception rules.

AOD-9604 fails steps 1 and 2 and triggers step 4. That combination places it firmly outside the lawful compounding channel in South Carolina.

What South Carolina Patients Should Know Before Seeking AOD-9604

Patients who have heard about AOD-9604 from social media, podcasts, or fitness communities often ask three questions: Is it safe? Is it legal? Can I get it from a doctor?

Safety Cannot Be Assumed

Because AOD-9604 sold outside licensed pharmacy channels has no guaranteed potency, sterility, or purity, patients bear the full safety risk. A 2020 analysis published in JAMA found that 28% of compounded injectable drugs sampled from non-503B sources failed at least one USP sterility or potency standard [10]. That failure rate applies to a broad category of compounds, not AOD-9604 specifically, but the underlying quality-control concern is directly relevant.

Legitimate Alternatives Are Available

For patients seeking medically supervised weight loss in South Carolina, multiple FDA-approved options exist. Semaglutide 2.4 mg (Wegovy), tirzepatide 15 mg (Zepbound), and naltrexone-bupropion (Contrave) are all approved, covered by some insurers, and available through licensed South Carolina pharmacies with a physician prescription. The Endocrine Society's 2023 obesity pharmacotherapy guidelines recommend initiating an FDA-approved GLP-1 receptor agonist as first-line pharmacotherapy for adults with a BMI ≥30 or BMI ≥27 with a weight-related comorbidity [11].

Talking to a South Carolina Physician

A board-certified physician in South Carolina cannot lawfully write a prescription for AOD-9604 to be filled at a licensed South Carolina pharmacy under current FDA rules. A physician who does so, and a pharmacist who fills it, risk regulatory action. Patients who receive such a prescription should ask the prescriber to document explicitly which regulatory pathway they believe applies and to disclose any financial relationship with the vendor supplying the compound. That documentation matters if an adverse event occurs.

Federal Enforcement Trends

The FDA and FTC have stepped up enforcement against unapproved peptide compounds since 2021. In February 2024, the FDA issued warning letters to seven compounding pharmacies marketing BPC-157 and related peptides as injectable products for human use, citing violations of 21 U.S.C. § 331(a) and (d) [4]. AOD-9604 has not been the subject of a named public warning letter as of this writing, but it falls under the same statutory framework that produced those letters. Enforcement actions tend to follow market growth: as demand for a compound rises, so does FDA's interest in policing unlicensed supply chains.

The DEA separately monitors peptides that may have anabolic or performance-enhancing properties for potential scheduling. AOD-9604 has not been scheduled, but the agency's Designer Anabolic Steroid Control Act (DASCA) authorities and analog scheduling powers give it tools to act quickly if a peptide develops a significant illicit-use market.

Frequently Asked Questions